| Target Price | ¥4,488.00 |
| Price | ¥3,461.00 |
| Potential |
29.67%
register free of charge
|
| Number of Estimates | 11 |
|
11 Analysts have issued a price target Kyushu Railway Company 2027 .
The average Kyushu Railway Company target price is ¥4,488.00.
This is
29.67%
register free of charge
¥5,040.00
45.62%
register free of charge
¥3,838.00
10.89%
register free of charge
|
|
| A rating was issued by 14 analysts: 10 Analysts recommend Kyushu Railway Company to buy, 4 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Kyushu Railway Company stock has an average upside potential 2027 of
29.67%
register free of charge
|
| Mar '26 |
2027 Estimates |
|
|---|---|---|
| Revenue Billion ¥ | 500.39 | 528.72 |
| 10.12% | 5.66% | |
| EBITDA Margin | 15.91% | 22.08% |
| 12.32% | 38.79% | |
| Net Margin | 9.09% | 9.56% |
| 5.43% | 5.21% |
12 Analysts have issued a sales forecast Kyushu Railway Company 2027 . The average Kyushu Railway Company sales estimate is
This results in the following potential growth metrics:
13 Kyushu Railway Company Analysts have issued a net profit forecast 2027. The average Kyushu Railway Company net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Mar '26 |
2027 Estimates |
|
|---|---|---|
| Earnings Per Share ¥ | 295.38 | 328.43 |
| 5.89% | 11.19% | |
| P/E | 10.54 | |
| EV/Sales | 1.84 |
13 Analysts have issued a Kyushu Railway Company forecast for earnings per share. The average Kyushu Railway Company EPS is
This results in the following potential growth metrics and future valuations:
Kyushu Railway Company...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


